Gene therapy and market access: the pharmaphorum podcast

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.

The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.